Your browser doesn't support javascript.
loading
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Ryoo, Baek-Yeol; Cheng, Ann-Li; Ren, Zhenggang; Kim, Tae-You; Pan, Hongming; Rau, Kun-Ming; Choi, Hye Jin; Park, Joong-Won; Kim, Jee Hyun; Yen, Chia Jui; Lim, Ho Yeong; Zhou, Dongli; Straub, Josef; Scheele, Juergen; Berghoff, Karin; Qin, Shukui.
Afiliação
  • Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. ryooby@amc.seoul.kr.
  • Cheng AL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Ren Z; Liver Cancer Institute, Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Kim TY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Pan H; School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
  • Rau KM; Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and E-Da Cancer Hospital, Kaohsiung, Taiwan.
  • Choi HJ; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Park JW; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang-si, Republic of Korea.
  • Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
  • Yen CJ; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan City, Taiwan.
  • Lim HY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Zhou D; EMD Serono Research & Development Institute, Inc. (A Business of Merck KGaA, Darmstadt, Germany), Billerica, MA, USA.
  • Straub J; Clinical Biomarker & Companion Diagnostics, Merck KGaA, Darmstadt, Germany.
  • Scheele J; Clinical Oncology, Global Research and Development, Merck KGaA, Darmstadt, Germany.
  • Berghoff K; Global Patient Safety Innovation, Merck KGaA, Darmstadt, Germany.
  • Qin S; Medical Oncology Department, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Br J Cancer ; 125(2): 200-208, 2021 07.
Article em En | MEDLINE | ID: mdl-33972742
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Piridazinas / Pirimidinas / Regulação para Cima / Carcinoma Hepatocelular / Proteínas Proto-Oncogênicas c-met / Sorafenibe / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Piridazinas / Pirimidinas / Regulação para Cima / Carcinoma Hepatocelular / Proteínas Proto-Oncogênicas c-met / Sorafenibe / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article